Synopsis: Natco Pharma shares rose 4% after the company launched affordable generic semaglutide multi-dose vials in India, starting at Rs 1,290 per month. The Day 1 launch after patent expiry, sharp pricing advantage, and plans to expand access through co-marketing and future pen-device launches boosted investor sentiment toward the stock.
The shares of this company, which is a vertically integrated, research and development-focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas, were in momentum today after the company announced the launch of generic semaglutide injection multi-dose vials in India.
With a market cap of Rs 17,357 crore, the shares of Natco Pharma Ltd jumped about 4% in today’s trading session and reached a high of Rs 973. When compared to its previous day’s closing price of Rs 937.05. The shares are trading at a PE of 11.1, whereas their industry’s PE is at 27.2, and they have given a return of more than 19% in the last 5 years.
Affordability Boost Seen as Key Trigger
NATCO Pharma shares have risen by 4% following the announcement of the launch of generic semaglutide injection multi-dose vials in India. The company is charging a starting price of Rs 1,290. This is a key trigger for the company’s shares. The company has launched the product under the brand names Semanat 2 mg/1.5 ml, Semanat 4 mg/3 ml, and Semafull 8 mg/3 ml. The 8mg/3ml formulation of the drug is priced at Rs 1,750.
This announcement has triggered the company’s shares because the company is entering the market on Day 1 of patent expiry. It is an early-mover advantage for the company. The company has also said it had received CDSCO approval in February 2026 to manufacture and market generic semaglutide in India for the formulation of both multi-dose vials and pen devices based on a clinical comparison study.
Huge Price Gap May Expand Patient Reach
One of the major reasons for such a positive response is pricing. The company claimed that its multi-dose vial is priced 70% lower than pen devices and 90% lower than the innovator’s brand. This makes it the most affordable GLP-1 available in India. This is one factor that could help the company widen its user base and improve compliance, especially for a chronic user base such as diabetes management.
The company has timed its launch well by being the first to launch generic semaglutide, a multi-dose vial, and customised syringes. The company is also willing to sell the product to third parties for co-marketing, which could help it grow faster. The launch of pen devices is scheduled for April 2026, adding another form factor to its product offerings.
The 4% gain in the stock is due to investor optimism that the affordable launch of semaglutide by NATCO could help it tap into a huge growth opportunity beyond its traditional image of being an oncology-focused company. The early mover advantage, coupled with competitive pricing and a wider access strategy, could help the company grow its formulations business in India.
Financials
The revenue from operations for the company stood at Rs 647 crore in Q3 FY26 compared to the Q3 FY25 revenue of Rs 475 crore, up by about 36 per cent YoY. Similarly, the net profit stood at Rs 151 crore in Q3 FY26, up compared to the Rs 132 crore profit in Q3 FY25.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Pharma Stock Jumps 4% After Launch of Generic Semaglutide Multi-Dose Vials in India appeared first on Trade Brains.